CORAVA THERAPEUTICS
WHY CORAVA
Important oncology innovation can be overlooked at every stage.
Some opportunities already have meaningful human evidence. Others are emerging from leading academic centers and innovative biotechnology platforms. Corava is built to recognize both — and to advance the programs where focused ownership, development discipline and capital efficiency can create disproportionate impact.
Emerging Science → Translational Evidence → Clinical Validation → Focused Development → Patient Impact
Innovation across the development continuum.
Clinically Validated Innovation
Meaningful human efficacy, safety or development evidence where focused execution can unlock additional patient value.
Biology-Led Innovation
Differentiated biology and translational science with a compelling path into defined oncology populations.
Pediatric & Rare Oncology Innovation
Medicines, targets and development opportunities where a pediatric-first strategy can create a viable and differentiated path forward.
Focused execution. Disciplined capital.
01 IDENTIFY
Find differentiated science and medicines across industry, biotechnology and leading academic institutions.
02 SELECT
Prioritize strong biology, meaningful evidence, high unmet need and focused development paths.
03 ADVANCE
Build fit-for-purpose clinical, regulatory, CMC and commercialization strategies.
04 COMPOUND
Use portfolio value creation to support the next generation of increasingly innovative oncology programs.
Innovation defines what we pursue. Capital efficiency defines how we build.
Pediatric-first. Oncology-wide.
Rare pediatric cancers remain an area of profound unmet need. Corava puts pediatric development at the center of its strategy while pursuing broader oncology opportunities that can strengthen the science, economics and long-term development of each medicine.
BLOOD
BRAIN
BONE
RARE SOLID TUMORS
Born from lived urgency. Built to turn innovation into impact.
Corava was founded by biopharmaceutical leaders with decades of experience in oncology development, commercialization and business development — and with a deeply personal understanding of what a childhood cancer diagnosis means for a family.
That combination of experience and urgency shapes how we select opportunities, deploy capital and advance medicines.
Leadership
Alex Garcia, MBA
Founder & CEO
20+ years across oncology, rare hematology and vaccines, spanning portfolio strategy, business development, commercialization and global product leadership.
Blake Tomkinson, PhD, MBA
Co-Founder, Head of Clinical Development
Clinical development leader with experience across hematologic and solid tumors, pediatric development and oncology search & evaluation.
Building the next generation of oncology innovation.
Corava partners with biotechnology companies, pharmaceutical organizations, investigators, academic institutions and patient organizations to identify and advance compelling oncology opportunities.
Partner With Corava
CONTACT